Acadia Gets Patent Runway To 2041, Trimming Annual Amortization To $9.9 Million

A new US patent allowance for Rett drug trofinetide lets Acadia spread Neuren-licensed intangibles over more years, from $10.9 million to $9.9 million.

Share
Acadia Gets Patent Runway To 2041, Trimming Annual Amortization To $9.9 Million

Acadia Pharmaceuticals, which develops drugs for neurological and rare diseases, will now amortize its Neuren-licensed Rett syndrome intangibles through March 2041 instead of July 2036, according to its 10-Q filed Thursday. The longer clock cuts projected yearly amortization to $9.9 million from $10.9 million.

A longer patent clock

The change follows a September notice of allowance from the US Patent and Trademark Office for a patent covering weight-banded dosing of trofinetide, the drug sold as DAYBUE. The company says it extends US protection from July 2036 to March 2041, and the remaining book value will be written off on a straight-line basis starting in October 2026.

The prior quarter's filing projected $5.4 million of amortization for the rest of 2026 and $10.9 million for each later year. The new filing projects $2.5 million for the rest of 2026 and $9.9 million for each of the five following fiscal years.

Acadia has capitalized $173.8 million in total as intangible assets under its Neuren license.

A $35 million European asset

A $35.0 million asset tied to the European Commission's August authorization of DAYBU, the European brand name, is now on the books. It will be amortized through the middle of 2038.

The matching Neuren milestone payment had not been paid at September 30, 2026. Acadia says it will pay within 60 days of its first commercial sale in the EU, which the filing places in October 2026, and the amount sits in accrued liabilities.

The company's results release said DAYBU launched in Germany in early October. Nine-month net sales of NUPLAZID and DAYBUE together were $918.3 million, against $787.5 million a year earlier.

Pipeline and courtroom dates

The Phase 2 RADIANT study of remlifanserin in Alzheimer's disease psychosis narrowly missed its main goal (p=0.0603). Acadia plans to keep enrolling its two Phase 3 studies at the 60 mg dose and drop the 30 mg arm.

In the NUPLAZID patent appeal against MSN and Aurobindo, the filing lists oral argument at the Federal Circuit for November 9, 2026. Separately, Acadia settled the Pimavanserin III case with Zydus, which may launch a generic 34 mg tablet on April 1, 2032, subject to triggers for earlier launch.

The Federal Circuit hears the NUPLAZID patent appeal on November 9, 2026, and the $35.0 million Neuren payment falls due within 60 days of the first EU sale.

Sources

More on Acadia Pharmaceuticals

All Acadia Pharmaceuticals (ACAD) coverage →